Jubilant Life Sciences donates 1000 vials of COVID-19 medicine Remdesivir to UP CM

Chief Minister of Uttar Pradesh Yogi Adityanath received Remdesivir (‘JUBI-R’) from Shyam S. Bhartia, Chairman, Jubilant Life Sciences Limited. This COVID-19 medicine was researched at Jubilant’s Noida R&D facilities.

On the occasion, Shri Yogi Adityanath said, “Remdesivir is an effective medicine in the treatment of severe COVID-19 cases. In this critical situation, I am pleased that this medicine was made available by Jubilant in the quick time of two and a half months.”

Jubilant has a large presence in UP. The CM also invited Jubilant to make further investments and look at the opportunities in the pharmaceutical sector. In May 2020, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc., that granted it the right to register, manufacture and sell Gilead’s investigational drug Remdesivir in 127 countries including India.

Jubilant, recently launched Remdesivir injection under the brand name ‘JUBI-R’ in the Indian market. The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the Company’s distribution network. Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the USFDA for treatment of suspected or laboratory-confirmed COVID-19.

“It gives us immense pleasure and satisfaction to present ‘JUBI-R’ the life-saving medicine to Hon’ble Chief Minister of Uttar Pradesh Shri Yogi Adityanath. We are delighted to support the Uttar Pradesh Government in its fight against COVID-19 by donating 1000 vials of JUBI-R (Remdesivir) through our CSR arm, the Jubilant Bhartia Foundation. We are thankful to the Uttar Pradesh Government for its support in producing this critical drug in a short span of time. Jubilant Life Sciences remains committed to the cause of providing leading healthcare solutions addressing the needs of the patients,” said Shyam S. Bhartia, Chairman, Jubilant Life Sciences Limited.

Disclaimer: This media release is auto-generated. The CSR Journal is not responsible for the content